Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors.
Cai
Jiaqiang
J
Merck Research Laboratories, MSD, Newhouse, Lanarkshire, United Kingdom. jiaqiang.cai@merck.com
Robinson
John
J
Belshaw
Simone
S
Everett
Kathryn
K
Fradera
Xavier
X
van Zeeland
Mario
M
van Berkom
Leon
L
van Rijnsbergen
Peter
P
Popplestone
Lucy
L
Baugh
Mark
M
Dempster
Maureen
M
Bruin
John
J
Hamilton
William
W
Kinghorn
Emma
E
Westwood
Paul
P
Kerr
Jennifer
J
Rankovic
Zoran
Z
Arbuckle
Wullie
W
Bennett
D Jonathan
DJ
Jones
Philip S
PS
Long
Clive
C
Martin
Iain
I
Uitdehaag
Joost C M
JC
Meulemans
Tommi
T
D000577:Amides / Q000138:chemical synthesis / Q000494:pharmacology; D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D000818:Animals; D002403:Cathepsins / Q000037:antagonists & inhibitors*; D015853:Cysteine Proteinase Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D005461:Fluorine; D006801:Humans; D007659:Ketones; D013329:Structure-Activity Relationship
D000577:Amides; D000814:Aniline Compounds; D015853:Cysteine Proteinase Inhibitors; D007659:Ketones; D005461:Fluorine; D002403:Cathepsins; C028217:cathepsin S